Stock Market News
Diurnal losses widen ahead of maiden revenue
Clinical-stage pharmaceutical company Diurnal saw losses widen in the first half of its trading year as costs rose ahead of the launch of its maiden product.
In the six months leading to 31 December, Diurnal's pre-tax loss widened 35% to £7.8m as costs associated with the research and development of its endocrine-focused products rose to a combined £7.7m from £5.7m posted a year earlier.
Diurnal chief executive Martin Whitaker said the firm had made "significant steps" towards becoming a revenue-generating speciality pharma company in recent months, especially gaining regulatory approval of its first product. Alkindi, a drug designed to address the needs of paediatric patients with adrenal insufficiency that result from deficiency of the essential hormone cortisol, was approved in Europe earlier this year.
There was still cash and equivalents of £14m in the bank at the half year stage, down 45% year-on-year, while net assets nearly halved to £10.8m over the same period.
Separately, Diurnal announced on Monday that it had completed patient recruitment for the European phase III trial of Chronocort, its modified-release hydrocortisone product, and was also granted its first US and Japanese patents for the congenital adrenal hyperplasia drug.
"Our experience in the development, registration and preparation for launch of Alkindi will be invaluable in the progression of Chronocort towards potential approval and launch in 2020. This positive momentum is also reflected in our US programmes; we have made significant progress with the development of Alkindi and Chronocort for this important market, with activities to support the planned Alkindi Phase III regulatory package ongoing and Chronocort Phase III development expected to commence later in 2018," said Whitaker.
Diurnal expects to make maiden revenue in the second half of 2018.
As of 1340 GMT, shares had gained 1.90% to 215.00p.
In the six months leading to 31 December, Diurnal's pre-tax loss widened 35% to £7.8m as costs associated with the research and development of its endocrine-focused products rose to a combined £7.7m from £5.7m posted a year earlier.
Diurnal chief executive Martin Whitaker said the firm had made "significant steps" towards becoming a revenue-generating speciality pharma company in recent months, especially gaining regulatory approval of its first product. Alkindi, a drug designed to address the needs of paediatric patients with adrenal insufficiency that result from deficiency of the essential hormone cortisol, was approved in Europe earlier this year.
There was still cash and equivalents of £14m in the bank at the half year stage, down 45% year-on-year, while net assets nearly halved to £10.8m over the same period.
Separately, Diurnal announced on Monday that it had completed patient recruitment for the European phase III trial of Chronocort, its modified-release hydrocortisone product, and was also granted its first US and Japanese patents for the congenital adrenal hyperplasia drug.
"Our experience in the development, registration and preparation for launch of Alkindi will be invaluable in the progression of Chronocort towards potential approval and launch in 2020. This positive momentum is also reflected in our US programmes; we have made significant progress with the development of Alkindi and Chronocort for this important market, with activities to support the planned Alkindi Phase III regulatory package ongoing and Chronocort Phase III development expected to commence later in 2018," said Whitaker.
Diurnal expects to make maiden revenue in the second half of 2018.
As of 1340 GMT, shares had gained 1.90% to 215.00p.
Related share prices |
---|
Diurnal Group (DNL) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price